Developing a vaccine to combat the SARS-CoV-2 virus was no small feat. Previously, the fastest vaccine ever developed took four years. Beginning in less than one year from initial development, people around the world are being inoculated with mRNA that hijacks the protein-building instructions cells use for nearly every bodily function.
Two of 2020’s heroes, BioNTech (NASDAQ: BNTX) and Moderna (NASDAQ: MRNA), have been working with the technology for more than a decade. A year after partnering with one of them, Pfizer‘s (NYSE: PFE) CEO thinks his company has it all figured out and is ready to go it alone. It’s a bold claim — but what if he’s right?